Recurrence patterns in a large contemporary cohort of patients with non-muscle invasive bladder cancer

Jasper P. Hof,[1] Lambertus A. Kiemeney,[1,2] Katja K.H. Aben,[1,3] Antoine G. van der Heijden,[2] Alina Vrieling,[1*] Sita H. Vermeulen[1*]

[1] Radboud university medical center, IQ Health science department, Nijmegen, The Netherlands

[2] Radboud university medical center, Department of Urology, Nijmegen, The Netherlands

[3] Netherlands Comprehensive Cancer Organization, Department of Research and Development, Utrecht, The Netherlands

[*]These authors share senior authorship

What does the study add?

Existing literature extensively addresses the risk of first recurrence as clinical outcome, leaving the risk, timing and characteristics of subsequent recurrences relatively understudied. Our study addresses this gap by investigating patterns of subsequent recurrences in a large contemporary population-based cohort.

We found that recurrence risk increases with number of prior recurrences, and subsequent tumours often manifest similar clinical characteristics within patients. Moreover, we discovered that over half of patients with primary low- or intermediate risk NMIBC who progress to muscle-invasive or metastatic disease experience a high risk recurrence before progression.

Abstract

Background and Objective: Patients with non-muscle invasive bladder cancer (NMIBC) frequently experience recurrences, yet, the timing and characteristics of subsequent recurrences are understudied. We aim to describe subsequent recurrences in a large, contemporary, population-based cohort.

Methods: We included 1,915 patients from the UroLife study and the Nijmegen Bladder Cancer Study, diagnosed with primary NMIBC between 2011 and 2021. The conditional 1-, 3- and 5-year risks of first to fourth recurrence were calculated using Kaplan Meier risks, stratified by clinicopathological factors. Patterns of subsequent tumours were described and visualised.

Key Findings and Limitations: We observed 671 first recurrences and 400 subsequent recurrences. The 3-year conditional recurrence risks for first, second and third recurrence were 31%, 45% and 54%, respectively, and were similar for NMIBC risk groups. Recurrence after a low-, intermediate- or high risk tumour (either primary or recurrent) was again of low-, intermediate- or high-risk in 74%, 62% and 44% of cases, respectively. Ten patients with low/intermediate risk NMIBC and 89 patients with high risk NMIBC progressed to muscle-invasive or metastatic bladder cancer. Seven out of these ten (70%) and 13 out of these 89 (15%) patients had a high risk recurrence before progression. This study was limited to a patient cohort from The Netherlands.

Conclusions and Clinical Implications: Our study provides novel and reliable estimates of recurrence rates and patterns in NMIBC from a large, contemporary, population-based cohort. Recurring NMIBC tumours often exhibit similar clinicopathological characteristics, and patients with primary low- or intermediate-risk NMIBC who progress to MIBC/mBC often have a high-risk recurrence before progression. These results can inform research into NMIBC recurrences and surveillance schedules.

Patient Summary

Our research focused on the timing and characteristics of recurring tumours among patients with non-muscle invasive bladder cancer. We showed that a recurring tumour is often of a similar type as the previous tumour. We also found that for patients with initial low- or intermediate risk tumours, a progression to muscle-invasive bladder cancer is often preceded by a high risk recurrence.

Keywords: bladder cancer; recurrence; progression; recurrent event analysis; risk stratification

57 **Introduction**

58 Approximately 75% of patients with bladder cancer are diagnosed with non-muscle invasive bladder
59 cancer (NMIBC), which is generally associated with a favourable survival (1-3). Yet, patients with
60 NMIBC face a high risk of recurrence and a substantial risk of progression to muscle-invasive bladder
61 cancer (MIBC) or metastatic disease (mBC) (1), necessitating an intensive follow-up schedule with
62 frequent invasive cystoscopies (2, 3).

63 Extensive research has been conducted into the clinical and pathological characteristics that predict
64 NMIBC recurrence and progression (4-11). Resulting risk classification models that classify NMIBC
65 tumours into low-, intermediate-, high-, or very high risk are used in clinical practice (3, 12).
66 However, most studies primarily focused on the first recurrence as clinical outcome, while the risk
67 and timing of subsequent recurrences remain relatively understudied. Yet, subsequent recurrences
68 have been reported to comprise 47% up to 62% of all observed recurrences (11, 13-16).

69 Although prior recurrence is a predictor in NMIBC risk classifications (5, 14), data on risks of
70 subsequent NMIBC recurrences are limited (11, 14, 15, 17, 18), and no study has explored the
71 patterns of tumour characteristics of these recurrences, including risk group classification. Previous
72 studies suffer from limitations such as the use of data that can now be considered outdated (14, 16),
73 relatively small sample sizes (15, 17), or restriction to an intermediate risk group (17). A more
74 comprehensive understanding of contemporary patterns of NMIBC recurrences may facilitate
75 research into mechanisms of recurrence and progression, improved risk classification, and novel
76 treatment and follow-up schedules.

77 In this study, we evaluated the timing and characteristics of recurrences of patients diagnosed with
78 NMIBC. All analyses were performed for the total cohort and stratified by risk group of the primary
79 tumour, which was based on a modified version of the EAU risk classification. We used two large
80 population-based Dutch bladder cancer cohorts: the UroLife study and the Nijmegen Bladder Cancer

Study (NBCS), in which recurrences were systematically registered, providing a robust foundation for our investigation.

83 **Materials and Methods**

84 Study population

85 Patients diagnosed with NMIBC were selected from two large Dutch bladder cancer cohorts. Both
86 cohorts identified eligible patients through the Netherlands Cancer Registry (NCR), which records
87 data from all cancers diagnosed in The Netherlands since 1989. One cohort is the UroLife study (19)
88 (N = 1,515), which is a prospective multicenter cohort study conducted in 22 hospitals in the east,
89 south and central parts of The Netherlands. Eligible patients were between 18 and 80 years old,
90 underwent a TURBT, and were newly diagnosed with histologically confirmed primary NMIBC of
91 stages Ta (May 2014-April 2017), T1 (May 2014-April 2021), or Tis (May 2014-April 2017). Patients
92 were invited for participation approximately 4 weeks after diagnosis. Response rate was 52% and
93 participants were comparable to patients declining participation with respect to age, sex, tumour
94 stage and tumour grade. Ethical approval was provided by the Committee for Human Research
95 region Arnhem-Nijmegen (CMO 2013-494).

96 The other cohort is the Nijmegen Bladder Cancer Study (20) (NBCS). During the period 1995-2015,
97 patients diagnosed with bladder cancer in one of seven hospitals in the eastern part of The
98 Netherlands were enrolled in the study. Patients were considered eligible if diagnosed at or before
99 the age of 75, alive at time of invitation for the study and able to read/understand the Dutch
100 language. Invitation was performed in six separate phases or batches. For the current study, we only
101 used the three most recent NBCS batches with patients who were diagnosed between 2011-2015
102 and invited for participation in 2017 and 2019 (N = 472). The NBCS was approved by the Committee
103 for Human Research region Arnhem-Nijmegen (CMO 2005-315).

104 Patients who participated both in UroLife and the NBCS were identified (N = 36) via linkage to the
105 NCR database and the duplicate record with the shortest follow-up time was omitted. Patients with
106 upper tract urothelial carcinoma before (N = 10) or within 3 months of primary diagnosis (N = 26)
107 were excluded. For both UroLife and NBCS, relevant data for this study on patient (age, sex) and

108 tumour characteristics (tumour stage, tumour grade, CIS, focality), and outcomes were obtained by a
109 medical file review by NCR data managers.

110 Treatment and follow-up of patients with NMIBC in The Netherlands is according to the Dutch
111 Urology Association (NVU) guidelines, which are based on the EAU guidelines. However, urologists
112 may deviate from guidelines in their clinical practice.

113 Definition of recurrence and progression

114 Recurrence is defined as either a (i) histologically confirmed bladder tumour based on a trans-
115 urethral resection of bladder tumour (TURBT), (ii) report of fulguration, (iii) histologically confirmed
116 bladder tumour found after cystectomy, or (iv) progression to MIBC or mBC after an initial NMIBC
117 diagnosis. Fulguration only counted as recurrence if it occurred at least six months after previous
118 recurrence, and was coded as TaG1 recurrence.

119 Notably, a recurrence can only occur after the patient achieved a 'tumour-free status'. The definition
120 for tumour-free status depends on the stage of the previous bladder tumour:

121 • For stage Ta or T1 tumours, an individual was considered tumour-free after undergoing
122 radical TURBT or re-TURBT, or, in case of nonradical (re-)TURBT, after tumour-negative
123 cystoscopy;
124 • For stage Tis or concomitant carcinoma in situ (CIS), an individual was considered tumour-
125 free after tumour-negative cystoscopy, and, if available, negative cytology. In cases where a
126 biopsy was performed, a negative result was required.

127 Notably, the requirement for negative cystoscopy and, if available, negative cytology and biopsies
128 ensured that for (concomitant) CIS, only those patients who had a complete response after
129 treatment were at risk of recurrences. As a result, 42 patients with primary (concomitant) CIS who
130 were never at risk of recurrence were excluded from analysis of recurrence. However, they remained
131 at risk of progression and were hence included in the progression analysis. Progression to MIBC or

132 mBC was defined as (i) the occurrence of a bladder tumour of stage T2 or higher, confirmed by
133 pathology or imaging, (ii) positive lymph node status, or (iii) distant metastasis.

134 Patients were no longer at risk of recurrences after either (i) the last contact between patient and
135 urologist; (ii) radical cystectomy; (iii) progression to MIBC or mBC; or (iv) diagnosis of another type of
136 cancer with metastasis, whichever came first. Patients were no longer at risk of progression to
137 MIBC/mBC after either (i) the last contact between patient and urologist; or (ii) diagnosis of another
138 type of cancer with metastasis, whichever came first. Recurrence-free survival was defined as the
139 time between the date of achieving the tumour-free status and date of subsequent recurrence or
140 end of at-risk period, whichever came first.

141 Definition of risk groups

142 Bladder tumours were categorized based on the EAU risk group classification (2021) by Sylvester *et*
143 *al.*, which is based on stage, grade, (concomitant) CIS, prior recurrence, focality, age, and tumour size
144 (5). We however adopted a slightly modified version in which prior NMIBC recurrence was not
145 included as risk factor, to ensure comparable classification of primary and recurrent bladder tumours
146 (see **Supplemental Table 1**). Also, tumour diameter was omitted, since this was not systematically
147 registered in the medical records by Dutch urologists and therefore mostly missing. Consequently, a
148 small percentage of tumours was assigned to a lower risk group compared to the EAU risk group
149 classification.

150 Data analysis

151 We assessed the 1-year, 3-year, and 5-year risk of first to fourth recurrence, conditional on prior
152 recurrence, based on Kaplan-Meier (KM) risk. To investigate whether recurrence patterns differ by
153 recency of diagnosis, we also performed these analyses separately for patients with a primary NMIBC
154 diagnosis before and after 2016 (median year of diagnosis). We also stratified KM analyses by
155 treatment, as NMIBC prognosis is affected by treatment. In addition, we stratified the KM risks of

first to fourth recurrence by sex to explore possible sex-specific recurrence patterns, as women have been reported to have poorer NMIBC prognosis (21).

Next, we described the transitions between risk groups, grade, stage, and tumour location across subsequent recurrences within patients. These were also visualised using alluvial diagrams. All KM risks and transitions between risk groups across subsequent recurrences were evaluated for the total cohort and stratified by risk group of the primary tumour. Finally, we described the recurrence patterns of the patients who progressed to MIBC or mBC using swimmer plots.

All analyses were performed in R (version 4.1.3). KM plots, alluvial diagrams and swimmer plots were visualised using the ggplot2 package (version 3.3.6).

166 **Results**

167 Cohort characteristics

168 Patient and tumour characteristics at time of primary diagnosis and at time of first to fourth
169 recurrence are described in detail in **Table 1**. A total of 1,915 patients with a primary diagnosis of
170 NMIBC were included, and 1,071 recurrences were observed. In addition, 99 patients progressed to
171 MIBC or mBC. The median follow-up time for the complete cohort was 59 months (interquartile
172 range (IQR): 38-67 months) and varied per risk group due to the extended inclusion of T1 patients in
173 the UroLife study. Median follow-up times for low, intermediate, high, and very high risk NMIBC
174 were respectively 62, 62, 46, and 31 months. The median age at initial diagnosis was 67 years (range:
175 18-80 years); 79% of the population was male.

176 Details of the treatment of primary tumours, categorized by risk group, are provided in **Table 2**.
177 Single postoperative instillation of chemotherapy was applied in 61% of low risk patients. High- and
178 very high risk papillary tumours underwent a re-TURBT in 72% and 82% of cases. Induction BCG
179 therapy was administered to 74% of high risk and 68% of very high risk primary tumours. In total, 44
180 patients underwent radical cystectomy for the primary tumour, and another 85 patients underwent
181 radical cystectomy later during follow-up: respectively 66 (10%) and 43 (27%) patients in the high-
182 and very high risk group were at some point treated with radical cystectomy.

183 Incidence and timing of recurrences

184 Of all observed recurrences, 671 (63%) were first recurrences. Among patients experiencing at least
185 one recurrence, 241 had at least one additional recurrence (i.e., two recurrences), 100 had at least
186 three recurrences and 39 had four recurrences or more.

187 KM curves for first to fourth recurrence are displayed in **Figure 1** (KM risks and 95% confidence
188 intervals in **Supplementary Table 2)**. The 1-year, 3-year, and 5-year KM risks of a first recurrence in
189 the total population were 15%, 31%, and 39%, respectively. We observed an increased risk for

190 subsequent recurrences: the 1-year, 3-year, and 5-year conditional KM recurrence risks of a second
191 recurrence after the first recurrence were 24%, 47%, and 52%, whereas the 1-year, 3-year, and 5-
192 year conditional KM recurrence risks of a third recurrence were even higher: 28%, 55%, and 60%,
193 respectively.

194 The 3-year KM risk of a first recurrence was similar for patients initially diagnosed with low-,
195 intermediate- and high-risk NMIBC: 30%, 32% and 30%, respectively. The 3-year KM risks of a second
196 recurrence after the first in the low-, intermediate and high-risk group were respectively 54%, 40%
197 and 47%.

198 We found similar recurrence risks of first to fourth recurrence after stratifying by sex and year of
199 diagnosis of primary tumour (**Supplementary Figure 1**). The impact of (indication of) treatment on
200 recurrence patterns is visualized in **Supplementary Figure 2**. Patients with primary low risk NMIBC
201 who were treated with a single postoperative chemotherapy instillation had comparable rates of
202 subsequent recurrences compared to those without. Primary high risk patients who received a re-
203 TURBT had lower rates of a first recurrence compared to patients without re-TURBT, and high risk
204 patients who received BCG induction had lower rates of first recurrence compared to patients not
205 receiving BCG induction therapy.

206 <u>Patterns of recurrences</u>

207 **Figure 2** displays all transitions between risk groups (low risk, intermediate risk, high or very high risk,
208 MIBC/mBC) between the primary tumour and subsequent recurrences. A recurrence after a low,
209 intermediate or high/very high risk tumour (either primary or recurrence) was again of low-,
210 intermediate- or high-risk in 74%, 62% and 44% of cases. Concordance was even higher when
211 focusing on grade and stage: a recurrence after low grade NMIBC (grade 1, 2, or 2A) was also of low
212 grade in 91% of cases, while a recurrence after high grade NMIBC was also of high grade in 80% of
213 cases. As for stage, 87% of recurrences after a Ta tumour were again of stage Ta. By contrast, only
214 25% of recurrences after a T1 tumour were again stage T1, while respectively 38%, 15% and 19% of

215 recurrences were Ta, (concomitant) CIS, or MIBC/mBC. Finally, 52% of recurrences after
216 (concomitant) CIS were again (concomitant) CIS (**Supplementary Figures 3 and 4**).Of patients with
217 primary low-risk NMIBC, 2.9%, 7.7%, and 10.4% developed a recurrence of intermediate or higher
218 risk within one year, three years, and five years after diagnosis, respectively.

219 Data on tumour location was available for 1,492 of the 1,915 primary tumours and 667 of the 1,071
220 recurrences. Alluvial plots that visualise the transitions of tumour locations are presented in
221 **Supplementary Figure 5**. In 78% of recurrences with tumour location available, the initial and
222 recurrent tumour were of the same coded site. For the subgroup of patients who received a re-
223 TURBT of an initial high- or very high risk tumour, 95 out of 140 recurrences (68%) with known
224 tumour location were of the same location as the previous tumour, and in the subgroup of patients
225 without re-TURBT, 52 out of 72 recurrences (72%) were of the same location.

226 In total, 99 patients progressed to MIBC or mBC. The disease course of these patients before
227 progression is visualised in **Figure 3**. Among the patients who progressed to MIBC or mBC, one
228 patient was diagnosed with primary low risk NMIBC, 9 with primary intermediate risk NMIBC, and 89
229 with primary high or very high risk NMIBC. The patient with primary low risk NMIBC had a
230 concomitant Ta + CIS recurrence before progressing to a T2 tumour. Among the 9 patients with
231 primary intermediate risk NMIBC, eight patients had a recurrence before progression. Six of them
232 had a high risk grade 2B or 3 recurrence before progressing to MIBC or mBC; the other two
233 experienced an intermediate risk recurrence before progression. Among the 10 patients with primary
234 low- or intermediate risk NMIBC who progressed to MIBC or mBC, four patients underwent a re-
235 TURT after TURBT of primary NMIBC. Seven patients out of 10 were at some point treated with
236 bacillus Calmette-Guérin (BCG), and eight out of 10 were treated with intravesical chemotherapy.

237 Among the 89 patients with primary high or very high risk NMIBC, 65 (73%) experienced progression
238 to stage 2 or higher, 29 (33%) were positive for lymph node metastasis and 35 (39%) experienced
239 distant metastasis. Only 19 (21%) patients experienced a recurrence before progression, of which 13

240 (15%) were high- or very high-risk. However, it should be noted that 9 of the 89 patients were never
241 tumour-free after primary (concomitant) CIS, and therefore never at risk of recurrence. Of these 89
242 patients, 42 underwent a re-TURBT after the TURBT of the primary tumour; 73 patients were at some
243 point treated with BCG, 37 were treated with multiple intravesical chemotherapy instillations for the
244 primary tumour, and 4 patients were never treated with intravesical chemo- or immunotherapy.

245

246 **Discussion**

247 In this large contemporary NMIBC cohort, we investigated patterns of multiple recurrences and
248 progression. We extensively described the transitions, timings and characteristics of subsequent
249 recurrences, as well as the course of the disease before progression to MIBC or mBC. Our findings
250 provide novel insights into the course of multiple recurrences in NMIBC under the current guidelines,
251 which can be used for future studies into surveillance schedules and facilitate research into NMIBC
252 recurrence mechanisms.

253 One pivotal outcome of our research is the observation that recurring tumours often manifest similar
254 clinicopathological characteristics, such as similar grade, stage, and risk group. This phenomenon was
255 previously reported in literature (15, 22), but now quantitatively substantiated by our study. Notably,
256 among the patients with primary low- or intermediate-risk NMIBC progressing to MIBC or mBC, we
257 observed a pattern in which progression was preceded by a high- or very high risk recurrence in 70%
258 of the patients. Conversely, primary high- or very high-risk NMIBC patients often exhibited a direct
259 progression to MIBC or mBC, with only 21% reporting any recurrence before progression. We also
260 observed that recurrence risks increased with the number of previous recurrences, in line with
261 current NMIBC risk calculators (5, 6)**.**

262 Most diagnoses of primary and recurrent bladder cancer are based on invasive and costly cystoscopy,
263 prompting the question whether patients could be monitored using a more relaxed schedule or
264 through urine markers instead. Based on our data, we cannot evaluate possible effects of changes in
265 surveillance schedules on NMIBC prognosis, as it remains unknown how tumours develop if detected
266 at a later point in time. We found that high grade recurrences often precede progression to MIBC or
267 mBC after low- or intermediate risk NMIBC. Urine markers work best in detecting high grade
268 recurrences (23), suggesting that for this subgroup, replacing cystoscopy checks with urine markers
269 could control MIBC/mBC risks by timely detection of high risk recurrences. Nonetheless,
270 comprehensive population-based data and increased understanding of the biological process of

271 progression is needed to assess the prognostic implications of substituting cystoscopy with urine
272 markers.

273 Prior studies have explored patterns of subsequent NMIBC recurrences, focusing on recurrence
274 mechanisms (15), statistical methods (14) or risk factors for multiple recurrences (13, 16-18). No
275 study reported the association between NMIBC risk groups and patterns of subsequent NMIBC or
276 MIBC/mBC development. Despite having a relatively long median follow-up time in the combined
277 dataset of UroLife and NBCS, other studies generally report higher recurrence rates (see
278 **Supplementary Table 4**). This may be due to our stricter definition of NMIBC recurrences, which
279 requires a tumour-free status before a recurrence, but also due to differences in patient populations
280 or intensification of NMIBC treatment over time.

281 Our study's primary strength lies in the size and quality of the combined datasets from UroLife and
282 NBCS. Clinical data were carefully collected in consultation with urologists and experts in bladder
283 cancer, enabling the in-depth exploration of recurrence patterns. The size of the dataset enabled the
284 stratification on various clinical characteristics of patients and visual presentation of tumour
285 characteristics up to the fourth recurrence. However, we recognise some limitations of the study.
286 The inclusion in the last four years of the UroLife study was restricted to T1 patients, resulting in a
287 relatively short follow-up time for this subgroup. Our population-based cohort was not treated in full
288 concordance with the current EAU guidelines. For example, only 61% of low- or intermediate risk
289 patients received a single post-operative instillation of chemotherapy. However, this is in line with
290 earlier reports on adherence to guidelines(12, 24, 25). Thus, our study offers a realistic insight into
291 patterns of multiple recurrences in a contemporary NMIBC population and differences in these
292 patterns according to treatment. We were unable to incorporate tumour size in our definition of
293 NMIBC risk groups. As a result, a small percentage of tumours may be assigned to a lower risk group
294 compared to assignment based on the EAU risk group classification. Also, prior recurrence was
295 omitted as risk factor, to allow for a direct comparison of intrinsic pathological characteristics among

296 subsequent tumours. Finally, this study was limited to two Dutch bladder cancer studies, and
297 replication in other populations is needed to externally validate our findings.

298 Conclusions

299 Using a large contemporary cohort, we revealed key patterns in NMIBC recurrences. We
300 demonstrated that recurring NMIBC tumours often manifest similar clinicopathological
301 characteristics. Over half of patients with primary low- or intermediate risk NMIBC who progress to
302 MIBC or mBC experience a high- or very high risk recurrence before progression, whereas primary
303 high risk NMIBC patients often exhibit direct progression to MIBC/mBC. The results of this study can
304 assist in the optimization of the design of future studies into factors that affect NMIBC outcomes.
305 Also, our study highlights relevant areas for further research, including further research into specific
306 patient subgroups with distinct recurrence patterns.

307

Funding/Support and role of the sponsor

SHV is supported by a grant from the Netherlands Organization for Scientific Research (NWO Vidi 91717334). The UroLife study was financially supported by Alpe d'HuZes/Dutch Cancer Society (KUN 2013-5926) and Dutch Cancer Society (2017-2/11179).

Acknowledgement

The authors thank all the patients who participated in UroLife and thank the following hospitals for their involvement in recruitment for the UroLife study: Amphia Ziekenhuis, Breda/Oosterhout (D.K.E. van der Schoot); Ziekenhuis Bernhoven, Uden (A.Q.H.J. Niemer); Canisius-Wilhelmina Ziekenhuis, Nijmegen (D.M. Somford); Catharina Ziekenhuis, Eindhoven (E.L. Koldewijn); Deventer Ziekenhuis, Deventer (P.L.M. van den Tillaar); Elkerliek Ziekenhuis, Helmond (E.W. Stapper †, P.J. van Hest); Gelre Ziekenhuizen, Apeldoorn/Zutphen (D.M. Bochove-Overgaauw); Isala Klinieken, Zwolle (E. te Slaa); Jeroen Bosch Ziekenhuis, 's-Hertogenbosch (S. van der Meer); Meander Medisch Centrum, Amersfoort (F.S. van Rey); Medisch Spectrum Twente, Enschede (M. Asselman); Maxima Medisch Centrum, Veldhoven/Eindhoven (L.M.C.L. Fossion, K. de Laet); Maasziekenhuis Pantein, Boxmeer (E. van Boven); Radboudumc, Nijmegen; Rijnstate, Arnhem/Velp/Zevenaar (C.J. Wijburg); Slingeland Ziekenhuis, Doetinchem (A.D.H. Geboers); St. Anna Ziekenhuis, Geldrop (A. Sonneveld); Elisabeth-TweeSteden Ziekenhuis, Tilburg/Waalwijk (P.J.M. Kil, B.P. Wijsman); St. Jansdal Ziekenhuis, Harderwijk (W.J. Kniestedt); VieCuri, Venlo (G. Yurdakul, A.H.P. Meier); Ziekenhuis Gelderse Vallei, Ede (M.D.H. Kortleve); Ziekenhuisgroep Twente, Almelo/Hengelo (E.B. Cornel). The authors thank the registration team of the Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data for the Netherlands Cancer Registry as well as IKNL staff for scientific advice.

References

1. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4-34.
2. Witjes JA. Follow-up in non-muscle invasive bladder cancer: facts and future. World J Urol. 2021;39(11):4047-53.
3. Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75-94.
4. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430-42.
5. Sylvester RJ, Rodriguez O, Hernandez V, Turturica D, Bauerova L, Bruins HM, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021;79(4):480-8.
6. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-5; discussion 75-7.
7. Lammers RJM, Witjes WPJ, Hendricksen K, Caris CTM, Janzing-Pastors MHC, Witjes JA. Smoking Status Is a Risk Factor for Recurrence After Transurethral Resection of Non–Muscle-Invasive Bladder Cancer. European Urology. 2011;60(4):713-20.
8. Evers J, Grotenhuis AJ, Aben KKH, Kiemeney L, Vrieling A. No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression. PLoS One. 2020;15(3):e0229384.
9. Zuniga KB, Graff RE, Feiger DB, Meng MV, Porten SP, Kenfield SA. Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions. Bladder Cancer. 2020;6(1):9-23.
10. Garg T, McMullen CK, Leo MC, O'Keeffe-Rosetti MC, Weinmann S, Nielsen ME. Predicting risk of multiple levels of recurrence and progression after initial diagnosis of nonmuscle-invasive bladder cancer in a multisite, community-based cohort. Cancer. 2021;127(4):520-7.
11. Deng N, Chen JX, Chen LW, Qiu SP, Li XF, Wang DH. Shorter recurrence-free survival time, higher risk of multiple recurrences: a retrospective study of non-muscle invasive bladder cancer after transurethral resection. Chin Med J (Engl). 2012;125(20):3681-6.
12. Hendricksen K, Aziz A, Bes P, Chun FK-H, Dobruch J, Kluth LA, et al. Discrepancy between European Association of urology guidelines and daily practice in the management of non–muscle-invasive bladder cancer: results of a European survey. European urology focus. 2019;5(4):681-8.
13. Waseda Y, Kobayashi S, Kanda E, Yokoyama M, Ishioka J, Matsuoka Y, et al. Impact of Bladder Neck Involvement on Recurrence in Patients With Non-muscle-invasive Bladder Cancer: An Analysis Based on a Time-dependent Model. Clin Genitourin Cancer. 2020;18(2):e62-e70.
14. Smedinga H, Steyerberg EW, Beukers W, van Klaveren D, Zwarthoff EC, Vergouwe Y. Prediction of Multiple Recurrent Events: A Comparison of Extended Cox Models in Bladder Cancer. Am J Epidemiol. 2017;186(5):612-23.
15. Bryan RT, Collins SI, Daykin MC, Zeegers MP, Cheng KK, Wallace DM, Sole GM. Mechanisms of recurrence of Ta/T1 bladder cancer. Ann R Coll Surg Engl. 2010;92(6):519-24.
16. Simon M, Bosset PO, Rouanne M, Benhamou S, Radulescu C, Molinie V, et al. Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score. PLoS One. 2019;14(2):e0211721.

17. Sharma V, Chamie K, Schoenberg M, Lee VS, Fero K, Lec P, et al. Natural history of multiple recurrences in intermediate-risk non-muscle invasive bladder cancer: lessons from a prospective cohort. Urology. 2022.
18. Miyake M, Nishimura N, Nakai Y, Fujii T, Owari T, Hori S, et al. Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method. Diagnostics (Basel). 2021;11(2).
19. de Goeij L, Westhoff E, Witjes JA, Aben KK, Kampman E, Kiemeney LA, Vrieling A. The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life. BMJ Open. 2019;9(10):e030396.
20. Grotenhuis AJ, Dudek AM, Verhaegh GW, Witjes JA, Aben KK, van der Marel SL, et al. Prognostic relevance of urinary bladder cancer susceptibility loci. PLoS One. 2014;9(2):e89164.
21. Uhlig A, Strauss A, Seif Amir Hosseini A, Lotz J, Trojan L, Schmid M, Uhlig J. Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2018;4(6):924-36.
22. Mariappan P, Smith G, Lamb AD, Grigor KM, Tolley DA. Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades. J Urol. 2007;177(3):867-75; discussion 75.
23. Maas M, Bedke J, Stenzl A, Todenhöfer T. Can urinary biomarkers replace cystoscopy? World journal of urology. 2019;37:1741-9.
24. Mori K, Miura N, Babjuk M, Karakiewicz PI, Mostafaei H, Laukhtina E, et al. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review. Urol Oncol. 2020;38(10):774-82.
25. Struck JP, Hennig MJ, Hupe MC, Moharam N, Paffenholz P, Nestler T, et al. Discrepancy between German S3 guideline recommendations and daily urologic practice in the management of nonmuscle invasive bladder cancer: results of a binational survey. Urologia Internationalis. 2023;107(1):35-45.

Tables and Figures

421 *Table 1.* ***Characteristics of all observed tumours in UroLife and the Nijmegen Bladder Cancer Study****.*
422 *Tumour characteristics are presented for all primary tumours (i.e., the complete cohort at time of*
423 *diagnosis), and all first, second, third and later recurrences, thereafter. Due to missing values, clinical*
424 *characteristics were not available for all tumours.*

	Primary[1]	Recurrence 1	Recurrence 2	Recurrence 3	Recurrence ≥4
N	1915	671	241	100	59
Age, median (IQR)	67 (61, 72)	67 (61, 73)	67 (61, 74)	68 (62, 75)	70 (64, 77)
Male sex, *n* (%)	1515 (79)	525 (78)	174 (72)	74 (74)	47 (80)
Stage, *n* (%)					
Ta	1113 (58)	472 (71)	184 (77)	80 (81)	49 (83)
T1	757 (40)	73 (11)	11 (5)	7 (7)	2 (3)
Tis	44 (2)	65 (10)	25 (10)	5 (5)	3 (5)
>2	-	41 (6)	10 (4)	3 (3)	1 (2)
Missing	1 (0)	9 (1)	8 (3)	4 (4)	4 (7)
Concomitant CIS, *n* (%)	233 (12)	32 (5)	7 (3)	3 (3)	2 (3)
N stage, *n* (%)					
0	1915 (100)	618 (97)	230 (99)	95 (99)	58 (98)
1	-	4 (1)	1 (0)	1 (1)	-
2	-	11 (2)	2 (1)	-	1 (2)
3	-	3 (0)	-	-	-
M stage, *n* (%)					
0	1915 (100)	613 (96)	228 (98)	95 (99)	58 (98)
1	-	2 (0)	-	-	-
1A	-	3 (0)	1 (0)	-	-
1B	-	20 (3)	4 (2)	1 (1)	1 (2)
Grade, *n* (%)					
1	328 (17)	130 (19)	61 (25)	22 (22)	13 (22)
2	443 (23)	136 (20)	51 (21)	19 (19)	11 (19)
2A	247 (13)	120 (18)	43 (18)	28 (28)	16 (27)
2B	152 (8)	53 (8)	21 (9)	13 (13)	11 (19)
3	688 (36)	164 (24)	37 (15)	13 (13)	4 (7)
Missing	57 (3)	66 (10)	28 (12)	5 (5)	4 (7)
Morphology, *n* (%)					
Urothelial carcinoma	1906 (100)	668 (100)	241 (100)	100 (100)	59 (100)
Small cell carcinoma	2 (0)	-	-	-	-
Mixed small cell carcinoma	3 (0)	2 (0)	-	-	-
Sarcomatoid	1 (0)	-	-	-	-
Micropappilary urothelial carcinoma	2 (0)	1 (0)	-	-	-
Mucinous adenocarcinoma	1 (0)	-	-	-	-
Lymphovascular invasion, *n* (%)	21 (1)	9 (1)	0 (0)	0 (0)	0 (0)
Risk group, *n* (%)					

Low Risk	519 (27)	199 (30)	81 (34)	37 (37)	16 (27)
Intermediate Risk	570 (30)	228 (34)	88 (37)	41 (41)	32 (54)
High Risk	641 (33)	138 (21)	43 (18)	14 (14)	7 (12)
Very High Risk	158 (8)	10 (1)	2 (1)	-	-
Missing	27 (1)	39 (6)	14 (6)	4 (4)	3 (5)
Focality, *n* (%)					
Multifocal	630 (33)	258 (38)	116 (48)	51 (51)	30 (51)
Unifocal	1257 (66)	405 (60)	116 (48)	42 (42)	27 (46)
Missing	28 (1)	8 (1)	9 (4)	7 (7)	2 (3)
Smoking[2], *n* (%)					
Never	293 (15)	-	-	-	-
Former	1179 (62)	-	-	-	-
Current	407 (21)	-	-	-	-
Missing	36 (2)	-	-	-	-

IQR: interquartile range. [1]The median follow-up time of patients experiencing no recurrences in the low-, intermediate-, high-, and very high-risk group were respectively, 62, 61, 52 and 40 months. [2]Smoking is only reported at primary diagnosis.

431 *Table 2.* ***Treatment of primary tumours, stratified by risk group****.*

	Low risk	Intermediate risk	High risk	Very high risk
N	519	570	641	158
re-TURBT*, *n* (%)	38 (7)	121 (21)	455 (71)	122 (77)
Radical cystectomy , *n* (%)	3 (1)	10 (2)	22 (3)	9 (6)
Single post-operative instillation of chemotherapy, ***n* (%)**	317 (61)	345 (61)	225 (35)	42 (27)
Mitomycine, ***n* (%)**[x]	205 (65)	258 (75)	164 (73)	32 (76)
Epirubicine, ***n* (%)**	103 (32)	59 (17)	52 (23)	7 (17)
Gemcitabine, ***n* (%)**	-	-	-	-
Unspecified, ***n* (%)**	9 (3)	28 (8)	9 (4)	3 (7)
Adjuvant chemotherapy, *n* (%)	107 (21)	185 (32)	139 (22)	18 (11)
Mitomycine, ***n* (%)**[x]	71 (66)	153 (83)	82 (60)	8 (44)
No. instillations, median (IQR)	9 (7, 9)	9 (7, 9)	8 (5, 9)	8 (4, 13)
Epirubicine, ***n* (%)**	33 (31)	17 (9)	14 (10)	1 (6)
No. instillations, median (IQR)	2 (1, 7)	6 (2, 8)	1 (1, 9)	1 (1, 1)
Gemcitabine, ***n* (%)**	-	6 (3)	39 (28)	8 (44)
No. instillations, median (IQR)	-	6 (6, 8)	6 (5, 11)	7 (6, 9)
Unspecified, ***n* (%)**	3 (3)	9 (5)	2 (1)	1 (6)
No. instillations, median (IQR)	11 (6, 12)	9 (7, 9)	-	-
Induction BCG[+], *n* (%)	3 (1)	85 (15)	472 (74)	108 (68)
No. instillations, median (IQR)	6 (6, 6)	6 (6, 6)	6 (6, 6)	6 (6, 6)
Maintenance BCG[+], *n* (%)	3 (1)	70 (12)	317 (49)	80 (51)
No. instillations, median (IQR)	10 (8, 12)	10 (9, 15)	9 (6, 15)	9 (3, 12)

432 *re-TURBT was performed for 446 (72%) out of 618 papillary high risk tumours and 110 (82%) out of 134 papillary very high
433 risk tumours. [x]Percentage of patients receiving a type of single instillation- or adjuvant chemotherapy is reported relative to
434 patient subgroup. [+]Induction BCG and maintenance BCG are defined in Supplementary Table 4.

435

436



Figure 1. ***Recurrence risk of NMIBC for the first to fourth recurrence, for complete cohort and stratified by risk group of primary tumour.*** *Recurrence risk is reported as Kaplan-Meier (KM) risks, based on time to recurrence since tumour-free status. For all KM curves, the 1-, 3-, and 5-year risks are included in the figure, and are reported with 95% confidence intervals in Supplementary Table 2. Note that some numbers at risk of risk groups may not add up to numbers of the full population due to missing values in risk groups.*



Figure 2. ***Alluvial diagram describing transitions of risk groups and progression within patients across subsequent recurrences, for complete cohort and stratified by risk group of primary tumour.*** *The vertical bars indicate the distribution of risk groups of tumours for the primary tumour and first to fourth recurrences. The numbers on top of each bar indicate the numbers of tumours and proportion in this (sub-)population. The stream fields between the blocks indicate the individual changes in risk group for subsequent recurrences. We note that risk group was not available for all tumours due to missing values.*



Figure 3. ***Swimmer plot describing the timing of recurrences, cystectomy and progression to MIBC or mBC for patients who progressed to MIBC or mBC****. Patients are categorized based on EAU group of primary tumour and ordered on the y-axis based on duration of follow-up time (depicted as grey line). All observed recurrences or cystectomy before progression to MIBC or mBC are plotted on the relevant y-value of the individual.*